Arcadia Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
RKDA$0.16-3.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Stockholders’ Equity
Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Income · Non-controlling Interest · TotalStockholders’Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at December 31, 2022 | 616,079 | $65 | $278,827 | $(257,859) | $— | $(133) | $20,900 |
| Issuance of shares related to March 2023 PIPE | 165,500 | — | 4,740 | — | — | — | 4,740 |
| Modification of warrants related to March 2023 PIPE | — | — | 219 | — | — | — | 219 |
| Issuance of shares related to August 2022 pre-funded warrants exercise | 56,813 | — | — | — | — | — | — |
| Issuance of shares related to March 2023 pre-funded warrants exercise | 425,834 | — | — | — | — | — | — |
| Issuance of shares related to employee stock purchase plan | 1,993 | — | 12 | — | — | — | 12 |
| Issuance of shares related to reverse stock split | 19,118 | — | — | — | — | — | — |
| Stock-based compensation | — | — | 717 | — | — | — | 717 |
| Unrealized gains on available-for-sale securities | — | — | — | — | 101 | — | 101 |
| Net loss | — | — | — | (13,981) | — | (5) | (13,986) |
| Balance at December 31, 2023 | 1,285,337 | $65 | $284,515 | $(271,840) | $101 | $(138) | $12,703 |
| Issuance of shares related to March 2023 pre-funded warrants exercise | 75,000 | — | — | — | — | — | — |
| Issuance of shares related to employee stock purchase plan | 4,603 | — | 9 | — | — | — | 9 |
| Stock-based compensation | — | — | 512 | — | — | — | 512 |
| Change in unrealized gains on available-for-sale securities | — | — | — | — | (101) | — | (101) |
| Write-down of non-controlling interest | — | — | — | — | — | 138 | 138 |
| Net loss | — | — | — | (7,038) | — | — | (7,038) |
| Balance at December 31, 2024 | 1,364,940 | $65 | $285,036 | $(278,878) | $— | $— | $6,223 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.